MASSOUD RASOOLI: Open Payments
NPI 1720587082 · GARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 82 payments from 14 companies in 2025. Trend: 2023 $416 · 2024 $731 · 2025 $1,514
Food & beverage: $1,514
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $575 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $320 |
| Ardelyx, Inc. | 10 | $230 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $66 |
| GENZYME CORPORATION | 2 | $60 |
| RedHill Biopharma Inc. | 2 | $49 |
| Madrigal Pharmaceuticals | 2 | $47 |
| Braintree Laboratories, Inc. | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
Products named: RINVOQ, ENTYVIO, IBSRELA, LINZESS, DUPIXENT, SKYRIZI, XIFAXAN, Talicia.
Industry payments across TX — which companies pay providers there.
